Sanofi (SNY) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$56.6B

Revenue (quarter)

$14.0B

Revenue growth (year over year)

+11.14%

Gross profit (trailing twelve months)

$41.2B

Gross margin

72.75%

Net income (trailing twelve months)

$4.6B

Net income (quarter)

$430.4M

Net income growth (year over year)

−90.73%

Net margin

8.17%

Return on equity

5.65%

EPS (trailing twelve months)

$1.90

Book value per share

$32.54

P/E (trailing twelve months)

21.21

Price to book

1.22

Debt to assets

46.10%

Payout ratio

61.10%

Dividend yield

5.07%

Company profile

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

• Is Sanofi (SNY) profitable?

  Yes. Sanofi earned $4.6B in net income over the trailing twelve months, a net margin of 8.17%.

• How much revenue does Sanofi (SNY) make?

  Sanofi generated $56.6B in revenue over the trailing twelve months, up 11.14% year over year.

• What is SNY's P/E ratio?

  Sanofi trades at 21.2 times trailing twelve-month earnings, on an EPS of $1.90.

• How do I buy stock in Sanofi (SNY)?

  SNY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.